The Vanguard Study is the first study being done by the new Cancer Screening Research Network (CSRN), a national clinical trials network created by the National Cancer Institute (NCI) to study new technologies for cancer screening.
This study is focused on multi-cancer detection (shortened to “MCD”) tests. MCD tests try to detect cancers using a single blood sample. We don’t yet know whether these tests can accurately find cancers at early, more curable stages or reduce your risk of dying from cancer. The purpose of the Vanguard Study is to better understand how well two different MCD screening tests work for people who are eligible to be screened for cancer.
This study will provide early information on how well MCD tests work as cancer screening tools. It will also help us understand how patients and their doctors make decisions about their care based on MCD test results.
People who participate will be asked to complete some questionnaires and provide information about your health and cancer risk factors. You will also be asked to give blood for use in this research.
Source: National Cancer Institute, Cancer Screening Research Network, https://prevention.cancer.gov/major-programs/cancer-screening-research-network-csrn, Accessed 11/11/2024.
- Complete 3 questionnaires over a two-year period
- Complete 2 blood draws over a two-year period
- Allow study researchers to review your relevant medical history, health records, and results of cancer-related testing over a two-year period
- Be a part of important research to help learn more about cancer screening.
- Possibility of getting results of multi-cancer detection blood tests if you are randomly assigned to one of the groups who will be given these tests.
- No cost to participate.
